Sage Therapeutics, Inc. (SAGE)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
As of 02:17PM EDT. Market open.
| Previous Close | 13.03 |
| Open | 12.93 |
| Bid | 13.13 x 100 |
| Ask | 13.19 x 100 |
| Day's Range | 12.93 - 13.61 |
| 52 Week Range | 10.92 - 59.99 |
| Volume | |
| Avg. Volume | 989,501 |
| Market Cap | 789.802M |
| Beta (5Y Monthly) | 0.85 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks
Sage (SAGE) Down 20% on Parkinson's Study Missing Primary Goal
Data from a mid-stage study show that Sage's (SAGE) experimental oral drug failed to show a statistically significant difference in treating patients with Parkinson's disease compared with a placebo.
- Zacks
Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Sage Therapeutics (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Investor's Business Daily
Sage Stock Collapses To Record Low After Parkinson's Drug Misses Its Mark
Sage Therapeutics said Wednesday its Parkinson's treatment failed in a midstage study, and Sage stock collapsed to a record low.
© 2024 Yahoo. All rights reserved.